View full meeting coverage »

Eyetube Meeting Coverage:

ASRS 2020



Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

RGX-314: Phase 1/2a Data

  Channels: Retina | Posted 7/28/2020

Arshad Khanani, MD, provides updates on visual and anatomic data from a phase 1/2a trial evaluating the safety and efficacy of RGX-314 (RegenxBio) in patients with wet AMD. New data from the two cohorts that received the highest dose of the drug are delivered during this summary of his ASRS 2020 lecture.

Clinical Trials • REGENXBIO • retina-meeting-recap • Wet AMD

6 / 10 Series: ASRS 2020